Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
William A. Zammarrelli, Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem R. Abu‐Rustum, Carol Aghajanian, Angela K. Green, Maria M. Rubinstein, Vicky Makker
Topics & Concepts
LenvatinibMedicinePembrolizumabCommon Terminology Criteria for Adverse EventsAdverse effectInternal medicineEndometrial cancerOncologyCancerImmunotherapyThyroid cancerEndometrial and Cervical Cancer TreatmentsHER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers